Xellence Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 15 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.05 M
- Revenue Growth 163.46%
- Profit Growth 516.89%
- Ebitda -25.56%
- Net Worth 7.43%
- Total Assets 65.76%
About Xellence Laboratories
Xellence Laboratories Private Limited (XLPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2006 and has a history of 19 years. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.05 M.
Jitender Bansal, Vivek Gambhir, and Divakar Sharma serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24232DL2006PTC144867
- Company No.
144867
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Xellence Laboratories?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Gambhir  | Director | 16-Jan-2006 | Current |
| Jitender Bansal | Director | 16-Jan-2006 | Current |
| Divakar Sharma | Director | 16-Jan-2006 | Current |
Financial Performance of Xellence Laboratories.
Xellence Laboratories Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 163.46% increase. The company also saw a substantial improvement in profitability, with a 516.89% increase in profit. The company's net worth moved up by a moderate rise of 7.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xellence Laboratories?
In 2021, Xellence Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ilex Biologicals Private LimitedJitender Bansal is a mutual person
Charges (Loans)
₹2.05 M
₹0
Charges Breakdown by Lending Institutions
- The Nainital Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Apr 2014 | The Nainital Bank Limited | ₹0.55 M | Open |
| 14 Dec 2012 | The Nainital Bank Limited | ₹1.50 M | Open |
How Many Employees Work at Xellence Laboratories?
Unlock and access historical data on people associated with Xellence Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xellence Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xellence Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
